Affimed to Participate in Fireside Chat at the H.C. Wainwright Cell Therapy Virtual Conference

Rhea-AI Summary

Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company, announced CEO Dr. Adi Hoess will participate in a fireside chat at the H.C. Wainwright Cell Therapy Conference on February 28, 2023, at 8:30 a.m. EST / 14:30 CET. The webcast will be available on Affimed’s website, with a replay accessible for 30 days post-event.

Affimed focuses on leveraging the innate immune system to fight cancer through its ROCK® platform, generating Innate Cell Engager (ICE®) molecules that target tumors. The company is headquartered in Heidelberg, Germany, with a mission to empower patients in their cancer battle.

HEIDELBERG, Germany, Feb. 22, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today its Chief Executive Officer, Dr. Adi Hoess, will participate in a fireside chat at the H.C. Wainwright Cell Therapy Conference on Tuesday, February 28, 2023, at 8:30 a.m. EST / 14:30 CET.

A live webcast of the fireside chat will be accessible on Affimed’s website at https://www.affimed.com/investors/webcasts-and-corporate-presentation/. A replay of the call will be archived on Affimed’s website for 30 days after the call.

For more information on the conference or to schedule a one-on-one meeting with Affimed management, please contact your conference representative or Alex Fudukidis via email at a.fudukidis@affimed.com or phone at +1 (917) 436-8102.

About Affimed N.V.
Affimed (Nasdaq: AFMD) is a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer by actualizing the untapped potential of the innate immune system. The Company’s proprietary ROCK^® platform enables a tumor-targeted approach to recognize and kill a range of hematologic and solid tumors, enabling a broad pipeline of wholly-owned and partnered single agent and combination therapy programs. The ROCK^® platform predictably generates customized innate cell engager (ICE^®) molecules, which use patients’ immune cells to destroy tumor cells. This innovative approach enabled Affimed to become the first company with a clinical-stage ICE^®. Headquartered in Heidelberg, Germany, with offices in New York, NY, Affimed is led by an experienced team of biotechnology and pharmaceutical leaders united by a bold vision to stop cancer from ever derailing patients’ lives. For more about the Company’s people, pipeline and partners, please visit: www.affimed.com.

Investor Relations Contact
Alexander Fudukidis
Director, Head of Investor Relations
E-Mail: a.fudukidis@affimed.com
Tel.: +1 (917) 436-8102

FAQ

When will Affimed's CEO participate in the H.C. Wainwright Cell Therapy Conference?

Dr. Adi Hoess will participate in the fireside chat on February 28, 2023, at 8:30 a.m. EST.

How can I watch the fireside chat featuring Affimed's CEO?

The fireside chat can be accessed via a live webcast on Affimed’s website.

What is the focus of Affimed N.V. as a clinical-stage company?

Affimed focuses on immuno-oncology, utilizing its ROCK® platform to harness the innate immune system against cancer.

What innovative approach does Affimed use in its cancer therapies?

Affimed utilizes Innate Cell Engager (ICE®) molecules to directly target and kill tumor cells.

Where is Affimed N.V. headquartered?

Affimed N.V. is headquartered in Heidelberg, Germany.